Neurotech International to launch clinical program into use of lead drug NTI164 to treat Rett Syndrome

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has launched a new clinical program into the use of daily oral cannabinoid-based drug to potentially treat Rett Syndrome in female patients.

Related Keywords

Australia ,Monash ,South Australia ,Thomas Duthy ,Neurotech International ,Paediatric Neurology Unit At Monash Medical Centre ,Australia Therapeutic Goods Administration ,Department Of Neurodevelopment Disability ,Rett Syndrome Research ,Rett Syndrome ,Royal Children ,Paediatric Neurology Unit ,Monash Medical ,Clinical Trial Notification ,Therapeutic Goods Administration ,Rett Syndrome Research Trust ,